3/20/25 16:35  | 3/18/25  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S.m | -230 | 8.77 | 0 | -26 | -10 | 226 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
1/17/25 16:30  | 1/15/25  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -157 | 7.23 | 0 | -22 | -8 | 252 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
1/10/25 16:30  | 1/8/25  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -174 | 8.22 | 0 | -21 | -7 | 274 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
12/3/24 17:48  | 11/29/24  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -223 | 4.56 | 0 | -49 | -14 | 295 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
11/21/24 15:07  | 11/21/24  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | M.d | 20 | 1.55 | 0 | 13 | 4 | 344 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
7/19/24 08:29  | 7/17/24  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -146 | 6.47 | 0 | -23 | -6 | 331 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
7/15/24 08:35  | 7/11/24  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -121 | 5.97 | 0 | -20 | -5 | 353 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
12/12/22 16:25  | 12/8/22  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | P.m | 30 | 1.88 | 0 | 16 | 64 | 41 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
8/2/21 20:09  | 7/29/21  | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | P | 200 | 8.00 | 0 | 25 | New | 25 | D |  |  |  |  |  |  |  |  |  |  |  |  |  |  |